Do you want to read an article? Please log in or register.
Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030
Viral Infections, Non-HIV
Related content
HIV / AIDSViral Infections, Non-HIV
Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study
Lancet Infect Dis.
Zelenev A, Li J, Mazhnaya A, Basu S, Altice FL
doi: 10.1016/
HIV / AIDS
Influence of hepatitis C virus co-infection and hepatitis C virus treatment on risk of chronic kidney disease in HIV-positive persons
AIDS.
Mocroft A, Ryom L, Oprea C, Li Q, Rauch A, Boesecke C, Uzdaviniene V, Sedlacek D, Llibre JM, Lacombe K, Nielsen LN, Florence E, Aho I, Chkhartishvili N, Szlavik J, Dragovic G, Leen C, Sambatakou H, Staub T, Laguno M, Elinav H, Tomažič J, Peters L, EuroSIDA study group.
doi: 10.1097/QAD.0000000000002570.
Viral Infections, Non-HIV
Patterns of drug, alcohol use and injection equipment sharing among people with recent injecting drug use or receiving opioid agonist treatment during and following hepatitis C virus treatment with direct-acting antiviral therapies: An international study
Clin Infect Dis.
Artenie AA, Cunningham EB, Dore GJ, Conway B, Dalgard O, Powis J, Bruggmann P, Hellard M, Cooper C, Read P, Feld JJ, Hajarizadeh B, Amin J, Lacombe K, Stedman C, Litwin AH, Marks P, Matthews GV, Quiene S, Erratt A, Bruneau J, Grebely J
doi: 10.1093/cid/ciz633.
Further Publications Anesthesiology
Hepatitis C virus elimination in Swiss opioid agonist therapy programmes - the SAMMSU cohort
Swiss Med Wkly
Bregenzer A, Bruggmann P, Castro E, Moriggia A, Rothen M, Thurnheer MC, Vernazza P, Scheidegger C
doi: 10.4414/smw.2021.20460
HIV / AIDSViral Infections, Non-HIV
Elimination of HCV as a public health concern among people who inject drugs by 2030 - What will it take to get there?
J Int AIDS Soc.
Grebely J, Dore GJ, Morin S, Rockstroh JK, Klein MB
doi: 10.7448/IAS.20.1.22146.
HIV / AIDS
A treatment as prevention trial to eliminate hepatitis C among men who have sex with men living with HIV in the Swiss HIV Cohort Study
Clin Infect Dis.
Braun DL, Hampel B, Ledergerber B, Grube C, Nguyen H, Künzler-Heule P, Shah C, Salazar-Vizcaya L, Conen A, Flepp M, Stöckle M, Béguelin C, Schmid P, Rougemont M, Delaloye J, Bernasconi E, Nicca D, Böni J, Rauch A, Kouyos RD, Günthard HF, Fehr JS
doi: 10.1093/cid/ciaa1124.
HIV / AIDS
Parenteral drug use as the main barrier to hepatitis C treatment uptake in HIV-infected patients
Rivero-Juarez A, Tellez F, Castaño-Carracedo M, Merino D, Espinosa N, Santos J, Macias J, Paniagua-García M, Zapata-Lopez A, Collado A, Gómez-Vidal MA, Perez-Stachowski J, Muñoz-Medina L, Fernandez-Fuertes E, Rivero A, Grupo de estudio de Hepatitis virales (HEPAVIR) of the Sociedad Andaluza de Enfermedades Infecciosas (SAEI).
doi: 10.1111/hiv.12715.
Viral Infections, Non-HIV
Effect of Hepatitis B virus on Steatosis in Hepatitis C virus co-infected subjects: a multi-center study and systematic review
J Viral Hepat.
Goossens N, de Vito C, Mangia A, Clément S, Cenderello G, Barrera F, D'Ambrosio R, Coppola N, Zampino R, Stanzione M, Adinolfi LE, Wedemeyer H, Semmo N, Müllhaupt B, Semela D, Malinverni R, Moradpour D, Heim M, Trincucci G, Rubbia-Brandt , Negro F
doi: 10.1111/jvh.12891.
RECOMMENDED
Viral Infections, Non-HIV
Elimination of hepatitis C in Europe: can WHO targets be achieved?
★ 2
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
Clin Microbiol Infect.
Maticic M, Lombardi A, Mondelli MU, Colombo M, ESCMID Study Group for Viral Hepatitis (ESGVH)
doi: 10.1016/j.cmi.2020.01.014.